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I. INTRODUCTION
The lure of biotechnology investment has finally transformed
Europe from passive recipient to active provider of biotechnology.1
For three decades, the United States appeared as the harbinger of the
biotechnology industry's development, a position now gradually
challenged by emerging European players.2 Great Britain appeared as
the first such player in the 1980s.3 Germany then followed in 1995
with its BioRegio Wettbewerb, a contest for government funding to
develop research centers or "biotech clusters. ' Germany continued
with the creation in 1997 of its own high technology market, Der
Neuer Markt, which offers German venture capital funds a market to
trade shares of biotechnology start-up companies.5 As a result, the
German biotechnology industry increased by 150 percent from 1996
to 1999.6 In the same period, France, Italy and other European
countries established Nasdaq-like financial markets which, as their
U.S. counterpart, attract venture capital and promote biotechnology
start-ups. Further, the French government increased its investment in
t B.S., Biological Sciences, Stanford University, 1996; J.D. Candidate, Santa Clara
University School of Law, 2002. The author would like to thank Philip L. McGarrigle, Jr., Vern
Norviel, Dr. Carol A. Stratford, and Allen B. Roberts for their assistance in researching this
issue and review of early drafts of this Comment.
I Darrell G. Dotson, Comment, The European Controversy Over Genetic-Engineering
Patents, 19 HOUS. J. INT'L L. 919, 919 (1997).
2 Oliver Morgan, Hi-Tech Britain Hijacked, THE OBSERVER, Nov. 26, 2000, at 5.
3 Id.
4 Morgan, supra note 2. The German government awarded 50 million marks each to
the areas of Munich, Cologne and Heidelberg for the construction of research centers. Karen
Lowry Miller, The Biotech Boom, NEWSWEEK, Oct. 30, 2000, at 56.
5 Morgan, supra note 2.
6 Id.
7 Miller, supra note 4.
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biotechnology research from $26 million to $260 million in the last
ten years.8 Despite such efforts to create an attractive market, total
biotechnology investment in Europe reached only $579 million in
1999, less than half of the corresponding investment in the United
States, but reflecting an increase of 53 percent over 1998. 9
Such an overview helps underscore the tensions over the ethical
and economic issues that accompany the growing importance of the
biotechnology industry to Europe. This Comment relies on the
University of Edinburgh's controversial European Patent (EP)
0695351 "Isolation, Selection and Propagation of Animal Transgenic
Stem Cells," granted on December 8, 1999, to examine some of these
tensions. 10 Part II presents Europe's current position on the patenting
of genetically modified organisms by studying the material articles of
the European Patent Convention (EPC) and the line of decisions
issued by the European Patent Office (EPO) concerning plant and
animal patents up to the grant of EP 0695351. Part III analyzes the
source of the scandal, namely Claim 48 of EP 0695351, in terms of its
significance and of the motivation of the applicant and the EPO in
respectively drafting and granting such a claim: "A method of
preparing a transgenic animal, said animal comprising a selectable
marker capable of differential expression in (a) desired stem cells and
(b) cells other than desired stem cells . . . ." Finally, the conclusion
examines the future of EP 0695351 and the most recent developments
in Europe for the protection of biotechnological inventions.
II. PROTECTION FOR GENETICALLY MODIFIED PLANTS AND
ANIMALS UNDER THE EPC
A. Material Articles of the EPC
Prior to 1973, a natural or legal person seeking patent rights in
Europe for an invention needed to apply to each national patent
office. The procedure was long, costly, and often led to an
inconsistent scope of protection between the countries." The EPC
emerged as the solution when the then contracting states ratified its
8 Id.
Id.
10 See European Patent No. 0695351 (issued Dec. 8, 1999).
11 Dotson, supra note 1, at 922.
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articles on October 5, 1973,12 and it came into effect in late 1977.13
With the preamble, the EPC states its goal: "[T]o strengthen co-
operation between the States of Europe in respect of the protection of
inventions, ... that such protection may be obtained in those States
by a single procedure for the grant of patents and by the establishment
of certain standard rules governing patents so granted.' 14 The EPC
thus enables a natural or legal person to submit one patent application
to its granting body, 15 the EPO, which if allowed gives that person a
"bundle" of national patents16-- one patent for each of the member
countries designated in the application. However, the equivalence
between the European patent and the multiple national patents is
illusory, because, although granted under the EPC, the patent's
validity, infringement and enforceability are defined by the national
courts.17 Thus, the scope of protection of the patent will vary with the
interpretation given to it by the various national courts and laws. 8
In November 2000, Turkey (TR) most recently joined the group
of EPC contracting states, which includes Austria (AT), Belgium
(BE), Switzerland (CH), Cyprus (CY), Germany (DE), Denmark
(DK), Spain (ES), Finland (FI), France (FR), the Hellenic Republic
(GR), Ireland (IE), Italy (IT), Liechtenstein (LI), Luxembourg (LU),
Monaco (MC), the Netherlands (NL), Portugal (PT), Sweden (SE)
and the United Kingdom (GB). 19 Together with the Extension States
of Albania (AL), Lithuania (LT), Latvia (LV), the former Yugoslav
Republic of Macedonia (MK), Romania (RO) and Slovenia (SI), an
inventor can submit a European patent application for a total of 26
countries and enter a European patent market open to over 450
million people. 20  Although the Extension States are not contracting
members of the EPC, they "have entered into an agreement . . . to
12 Convention on the Grant of European Patents (European Patent Convention), Oct. 5,
1973, available at http://www.european-patent-office.org/legal/epc (last visited Dec. 1, 2001)
[hereinafter EPC].
13 Press Release, European Patent Office, Turkey now a member state of the European
Patent Organization (Nov. 1, 2000) available at http://www.european-patent-
office.org/news/pressrel.
14 EPC, supra note 12.
15 Id. art. 4.
16 Id. art. 64.
17 Id.
18 Dotson, supra note 1, at 924.
19 EUROPEAN PATENT OFFICE, EPO MEMBER STATES, at http://www.european-patent-
office.org/epo/members.htm (last updated Nov. 2, 2001).
20 EPO press release dated Nov. 1, 2000, supra note 13.
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extend the protection conferred by European patent applications and
patents to their territory. 21
Before issuing as a patent, an application submitted to the EPO
must first satisfy the standards for patentability under Article 52(1):
"inventions which are susceptible of industrial application, which are
new and which involve an inventive step., 22 More specifically, the
"inventive step" requirement demands the application present a
technical problem then solved by the invention to illustrate that
invention's industrial applicability.2 3  U.S. statutory patent law
imposes parallel standards, simply under a different nomenclature.
Under the U.S. system, an invention must demonstrate usefulness,
2 4
non-obviousness, 25 and novelty26 (respectively industrial application,
inventive step, and novelty under the EPC). However, under U.S.
patent law, an invention must also show enablement2 7 and the best
mode.
28
The EPC standards for patentability may strike the unwary
applicant as straightforward, but their deceptive nature lies in broadly
stated requirements then restricted through the use of exceptions in
subsequent articles. Article 52(2) lists specific categories of
inventions excluded from patent protection, such as discoveries,
scientific theories, mathematical methods, aesthetic creations,
methods of doing business, and computer programs. 29  However,
Article 53 represents the EPC's true limiting provision concerning
patentable subject matter:
European patents shall not be granted in respect of:
(a) inventions the publication or exploitation of which would be
contrary to "ordre public" or morality, provided that the
exploitation shall not be deemed to be so contrary merely because
it is prohibited by law or regulation in some or all of the
Contracting States;
21 Id.
22 EPC, supra note 12, art. 52.
23 Akim F. Czmus, M.D., Comment, Biotechnology Protection in Japan, the European
Community, and the United States, 8 TEMP. INT'L & COMP. L.J. 435,438 (1994).
24 35 U.S.C. § 101 (1994).
25 Id. § 103.
26 Id. § 101-02.
27 Id. § 112.
28 The "best mode" requirement signifies the best mode contemplated by the inventor for
making and using his invention at the time of filing the patent application. Id.
29 EPC, supra note 12, art. 52.
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(b) plant or animal varieties or essentially biological processes for
the production of plants or animals; this provision does not apply
to microbiological processes or the products thereof.
30
This article restricts the scope of patentable subject matter under
sections (a) and (b) only to broaden it anew as an exception to the
exception in the second phrase of section (b).3' As a result of such
convoluted wording, plant or animal varieties seem unpatentable
under the EPC, except as the products of microbiological processes.
32
However, Part II.B. of this Comment will show the analysis of Article
53(b) is not so straightforward. Further, Article 53 offers perhaps the
best illustration of how the EPC falls short of its proposed goal of
"[establishing] . . . certain standard rules governing patents so
granted ' 33 by failing to explain the key concepts of the exceptions to
patentability.34  Indeed, the absence of binding definitions of
"contrary to 'ordre public' and morality," "essentially biological,"
and "microbiological" leaves the national courts of the EPC
contracting states free to interpret and apply these terms to patents,
and in doing so contradict one another.35
Once the Examining Division of the EPO reviews a patent
application for compliance with the requirements of patentability and
the exceptions to acceptable subject matter, it can either grant or
refuse the application. 36 In the case of a denial, the applicant may
then appeal to the Board of Appeal.37 The Board of Appeal in turn
can affirm the decision of the Examining Division or remit the
application to the Examining Division for further prosecution.38
Irrespective of how harmonious the examination procedure, the EPO
loses the ability to amend or revoke a patent once granted, except in
accordance with an opposition procedure. 39 There lies one of the
significant differences with the U.S. patent system, which allows the
Commissioner of Patents to order, on his own initiative, the
reexamination of a patent, following a substantial new question of
30 Id. art. 53.
31 KLARA GOLDBACH ET AL., PROTECTION OF BIOTECHNOLOGICAL MATTER UNDER
EUROPEAN AND GERMAN LAW 46 (Walter Franzke ed., 1997).
32 Id.
33 EPC, supra note 12, at Preamble.
34 Czmus, supra note 23, at 441-42.
Id.
36 EPC, supra note 12, art. 97.
37 Id. art. 106.
38 Id. art. 111.
39 See id. art. 102.
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patentability affecting a claim,40 and to issue a certificate canceling
such claim if the patentee fails to defeat the question.41 The EPC
compensates for the seemingly great limit on amendment and
revocation by allowing any person to file with the EPO a notice of
opposition to a European patent within nine months of the grant
date.42 The notice must only cite one of the grounds for opposition
listed in Article 100:
Opposition may only be filed on the grounds that:
(a) the subject-matter of the European patent is not patentable
within the terms of Articles 52 to 57;
(b) the European patent does not disclose the invention in a
manner sufficiently clear and complete for it to be carried out by a
person skilled in the art;
(c) the subject-matter of the European patent extends beyond the
content of the application as filed, or, if the patent was granted on
a divisional application or on a new application filed in accordance
with Article 61, beyond the content of the earlier application as
filed.43
The Opposing Division will hear the patentee and then take one
of three possible actions: revocation of the patent, if the ground for
opposition is prejudicial to its maintenance; rejection of the
opposition, if the ground for opposition is not prejudicial to the
maintenance of the patent in its unamended form; or amendment of
the patent, if pursuant to the patentee's suggested modifications the
patent and invention now comply with the EPC requirements.
44
B. Analysis of the relevant EPO Decisions
In addition to the text of the EPC provisions, an analysis of a
recent line of opinions by the EPO Technical Board of Appeal and
Enlarged Board of Appeal helps elucidate the scope of the protection
available in Europe for genetically modified organisms. Like the key
terms of Article 53 that they seek to clarify, these opinions often do
not dispose of all issues raised and at times even approach
inconsistency. Nonetheless, such a study is crucial for understanding
40 35 U.S.C. § 304 (1994).
41 Id. §§ 305-06.
42 EPC, supra note 12, art. 99.
43 Id. art. 100.
44 Id. art. 102.
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why the legal representative for the University of Edinburgh so
drafted Claim 48 of EP 0695351.
1. Decision T19/90
In 1985, Harvard University filed an application with the EPO
for a transgenic 45 non-human mammalian animal (preferably a rodent
such as a mouse) produced by introducing an activated oncogene into
the animal's chromosomal deoxyribonucleic acid (DNA); upon
incorporation into the genome, such oncogene increased the
probability of the animal developing cancerous tumors.46 In part for
the present discussion, the Examining Division (the "Division")
rejected the application by interpreting the term "animal varieties" in
Article 53(b) as excluding animals per se from patentability.47 Thus,
Claims 1, 17, and 18 included unacceptable subject matter in the form
of a method of producing a transgenic animal, the genetically
modified animal itself, but also its descendents through sexual
reproduction:
1. A method for producing a transgenic non-human mammalian
animal having an increased probability of developing neoplasms,
said method comprising introducing an activated oncogene
sequence into a non-human mammalian animal at a stage no later
than the 8-cell stage.
17. A transgenic non-human mammalian animal whose germ cells
and somatic cells contain an activated oncogene sequence
introduced into said animal, or an ancestor of said animal, at a
stage no later than the 8-cell stage, said oncogene optionally being
further defined according to any one of Claims 3 to 10.
18. An animal as claimed in Claim 17 which is a rodent.48
Harvard University appealed the decision of the Division to the
Technical Board of Appeal (the "Board"). On October 3, 1990, the
Board issued its landmark decision T 19/90 setting aside the
45 "The term 'transgenic animals' shall mean animals which contain a foreign DNA
sequence that is normally not observed in said animals." Goldbach, supra note 31, at 281.
"Such animals are produced from fertilized eggs injected with foreign DNA that is subsequently
incorporated into the genetic composition of the developing embryo." WILLIAM S. KLUG &
MICHAEL R. CUMMINGS, CONCEPTS OF GENETICS 237 (Sheri L. Snavely ed., Prentice Hall, Inc.
6th ed. 2000) (1983).
46 See European Patent No. 0169672 (issued May 13, 1992).
47 See HARVARD/Onco-mouse: Application 85 304 490.7, 5 EuR. PAT. OFF. REP. 4, 7
(1990).
48 Id. at 6.
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Division's decision and remitting the application for further
prosecution. 49  T 19/90 can be understood best as a three-part
explanation of the exceptions to patentability under Article 53(b):
1. animal varieties, 2. essentially biological processes, and 3.
microbiological processes.
First, the Board rested its interpretation of "animal varieties" on
its decision T 320/87 LUBRIZOL/Hybrid plants, which held that
exceptions to patentability should be strictly construed,50 and on
Article 177(1), stating that the English, French, and German texts of
the EPC are equally authentic." The Board identified a discrepancy
in the terminology used between the three texts of Article 53(b):
European patents shall not be granted in respect of:
(a)...
(b) plant or animal varieties or essentially biological processes for
the production of plants or animals; ....
Les brevets europdens ne sont pas d~livrrs pour:
(a)...
(b) les vari~tds vrgdtales ou les races animales ainsi que les
procrd~s essentiellement biologiques d'obtention de v~gdtaux ou
d'animaux; ....
Europdische Patente werden nicht erteilt ffir:
(a)...
(b) Pflanzensorten oder Tierarten sowie fir im wesentlichen
biologische Verfahren zur Zflchtung von Pflanzen oder Tieren;
52
Indeed, the French term races animales and the German term
Tierarten translate in English as animal breeds 53 and animal species
54
respectively, and as such the German term covers a higher taxonomic
order than both the English and French counterparts. 5 The Board's
49 HARvARD/Onco-mouse: T 19/90, 5 EUR. PAT. OFF. REP. 501, 513 (1990).
50 Id. at 502.
51 EPC, supra note 12, art. 177(1).
52 Id. art. 53(b).
53 COLLINS ROBERT FRENCH-ENGLISH ENGLISH-FRENCH DICTIONARY 740 (5th ed.
1998).
54 THE OXFORD-DUDEN GERMAN DICTIONARY 709 (rev. ed. 1997).
55 HARvARD/Onco-mouse: T 19/90, supra note 49, § 4.2, at 510.
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conceptualization of "higher taxonomic order" signifies the German
term Tierarten includes more complex organisms, which imparts this
term with a greater scope of exclusion and leads to narrower
protection for the invention. Thus, an applicant seeking protection for
a genetically modified animal must at most satisfy the limits on
patentability imposed by the German term Tierarten. In addition to
the language discrepancy, the Board noted the legislators could not
have intended to exclude animal varieties and animals as such from
patentable subject matter, and thus rejected this interpretation of
Article 53(b) by the Division.56  The legislators used the word
"animals" in a general sense and as a qualifier in "animal varieties,"
in the same section (b) of Article 53, which suggests that the terms
"animal varieties" (races animales, Tierarten) and "animals"
(animaux, Tiere) are not synonymous. The Board remitted the
application to the Division with the order to examine whether the
application's subject matter qualified as an "animal variety" within
the elucidated meaning of Article 53(b).5 8
Second, the Board confirmed the Division's interpretation of
"essentially biological processes" as meaning the opposite of man-
made transformations. 59 Claim 1 recites the method for producing a
transgenic non-human mammalian animal by injecting the oncogene
into a vector plasmid and transfecting a cell at an early embryonic
stage, or a fertilized oocyte no later than the 8-cell stage.60 Hence, if
the subject matter of the application survived the "animal variety"
exception on remand, the Division should hold the process claim 6l-
Claim 1-as patentable. The product claims,62 Claims 17 and 18,
presented a greater challenge, especially Claim 17, which covered the
transgenic animal produced according to the method of Claim 1 and
the descendents of such an animal. The transgenic animal resulted
from a man-made transformation, but its descendents could be the
outcome of the biological process of sexual reproduction and thus fall
under the "essentially biological processes" exclusion from
patentability.63 The Board concluded the Division's analysis of Claim
56 Id. § 4.4, at 510.
57 Id. § 4.6, at 510.
58 Id. § 4.8, at 511.
59 See id. §4.9.1, at511.
60 EP 0169672, supra note 46.
61 See generally DONALD S. CHISUM ET AL., PRINCIPLES OF PATENT LAW 753 (David L.
Shapiro ed., 1998) (for a definition of"process claim").
62 See generally id. (for a definition of "product claim").
63 See HARVARD/Onco-mouse: T 19/90, supra note 49, § 4.9.2, at 511-12.
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17 being an attempt to bypass the limitation under Article 53(b) by
combining a non-biological and a breeding process was incorrect.
64
Perhaps T 19/90's greatest flaw lies in the Board remitting this issue
to the Division without further guidance. The Board simply wrote:
"[T]his question may be left open for the time being since the basic
assertion in the contested Decision - that Claim 1965 circumvents
Article 53(b) EPC, and thus precludes the grant of a patent - is wrong
in any case. 66 The question referred to contemplates whether the
original transgenic animal and its descendents represent different
products.
Third, the Board rejected the Division's disposition of the
"microbiological processes" exclusion to patentability. The Division
justified avoiding an examination of whether the invention included a
microbiological process by stating that the second phrase of Article
53(b) failed to apply if the product-here a transgenic animal-was
excluded from patentability under the first phrase of the same
article.67 The Board concluded that the second phrase of Article 53(b)
must be read as an exception to the exception, thus reinstating the
general standards of patentability of Article 52(1) to microbiological
processes and the products thereof.
68
On remand, the Division finally granted the claims in dispute on
May 13, 1992.69 In part, the Division held on the issue of whether the
transgenic non-human mammalian animal qualified as an "animal
variety":
The only claims in the present patent application that are directed
to animals are generically drafted claims to non-human
"mammals" and to "rodents." Accordingly, the question to be
answered is whether or not the subject-matter of these claims is
covered by the term "animal variety" or its counterparts in the
other two official languages as referred above. Although the term
64 Id. § 4.9.2, at 512.
65 Applicant redrafted Claim 17 as Claim 19 in his first auxiliary request as part of his
appeal to the Technical Board of Appeal. Claim 19 is, for the most part, identical to Claim 17 of
the original patent application:
19. A transgenic non-human mammalian animal whose germ cells and somatic
cells contain an activated oncogene sequence introduced into said animal, or an
ancestor of said animal, at an embryonic stage, said oncogene optionally being
further defined according to one of Claims 3 to 10.
Id. § IV, at 505.
66 Id. § 4.9.2, at 512.
67 Id. § 4.10, at 512.
68 Id.
69 EP 0169672, supra note 46.
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"animal variety" is not entirely clear, in particular in view of the
differing wording in the three equally binding languages of the
EPC, it nevertheless can be stated with certainty that rodents or
even mammals constitute a taxonomic classification unit much
higher than species ("Tierart"). An "animal variety" or "race
animal" [sic] is a sub-unit of a species and therefore of even lower
ranking that a species. Accordingly, the subject-matter of the
claims to animals per se is considered not to be covered by the
above three terms of Article 53(b) EPC.7 °
The grant of the application as EP 0169672 did not mark the end of
the dispute. Pursuant to EPC Article 99, seventeen different parties,
including religious groups, animal rights organizations, legal and
political entities, environmental protection agencies, and private
individuals filed notices of opposition with the EPO to the Harvard
onco-mouse patent.71  The EPO Opposition Division held oral
proceedings related to these oppositions on November 21, 1995.72
Nonetheless, these proceedings yielded no definite resolution; the
hearings ended in confusion on November 24, 1995 with four EPO
officials leaving the room.73  The Opposition Division declined to
return an immediate decision and plainly stated that further notices of
opposition must be submitted in writing to a tribunal.74
For almost five years, the Opposition Division remained silent
while the patentee, Harvard University, impelled for a favorable
decision in light of the Enlarged Board of Appeal G 01/98 opinion
concerning transgenic plants.75 Finally, on September 20, 2000, the
70 HARVARD/Onco-mouse: Application 85 304 490.7, 6 EuR. PAT. OFF. REP. 525, 526
(1991).
71 List of entities that filed notices of opposition: Compassion in World Farming
Supporters et al.; Bundesverband der Tierversuchsgegner et al.; Okologisch Demokratische
Partei; Btichner Reinhard; Meinel A. et al., Fraktion Biundnis 90; Fuchs U. et al.; Fraktion
Bfindnis 90 Die Grunen im Bayer. Landtag; Evangelischer Stadtkirchenverband Koln;
Bundesland Hessen vertr. durch das Hessische Ministerium ftir Jugend, Familie und Gesundheit;
Koechlin F., Schenkelaars P. et al. "No Patents on Life"; Voggenhuber J. et al. Grilner Klub im
Parlament; Keine Patente auf Leben; Sylvia Hamberger et al. "Kein Patent auf Leben";
Bundeszentrale der Tierversuchsgegner Osterreichs; Wiener Tierschutzverein und
Zentralverband der Tierschutzvereine Osterreichs; Helletsberger H.; Deutsches Tierhilfswerk.
European Patent Register, at http://www.epoline.org/register.html (last updated Dec. 12, 2001)
(search for publication number EPO169672).
72 Id.
73 Tom Wilkie, "Onco-mouse " Spreads Confusion in Patent Office, THE INDEPENDENT,
Nov. 25, 1995, at 8, LEXIS, Nexis World Library, Allwld File.
74 Id.
75 E-mail from Philip L. McGarrigle Jr., Chief Intellectual Property Counsel,
Affymetrix, Inc. (Jan. 8, 2001, 08:51:43 PST) (on file with author). See below Part II.B.3. for a
discussion of G 01/98.
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EPO invited Harvard University, and sixteen different parties
advocating for the revocation of the onco-mouse patent, to request
that the opposition procedure be resumed.76  On May 9, 2001, the
EPO dispatched to all parties summons to three days of oral
proceedings, starting on November 6, 2001.77 At the close of the
second day of hearings, the Opposition Division ruled that Harvard
University's onco-mouse patent was maintained in amended form and
"the patent must be limited to transgenic rodents containing an
additional cancer gene., 78 In its press release, the EPO added that
either Harvard University or any of the opponents may appeal the
Opposition Division's ruling.
79
2. Decision T 356/93
Decision T 356/9380 contributes the next piece to what seems a
puzzle for the elucidation of the key terms of Article 53(b). On
October 10, 1990, the Examining Division granted European patent
No. 0242236 to its applicant Plant Genetic Systems. 81 The invention
claimed the production of plants and seeds resistant to the class of
herbicides known as glutamine synthetase inhibitors (GSIs), and thus
selectively protected against weeds and fungal diseases.82 The
organization Greenpeace then filed a notice of opposition declaring
the subject matter of the invention unpatentable under EPC Article
53(b)'s "plant varieties" exclusion. 83  The Opposition Division
rejected the notice and T 356/93 was issued as the Technical Board's
decision following Greenpeace's appeal.
The Technical Board wrote its "conclusions [were] not at
variance with Decision T 19/90,,,84 but in fact, T 356/93 directly
76 Press Release, European Patent Office, "Oncomouse" opposition proceedings resume
at EPO (Nov. 5,2001), available at http://www.european-patent-office.org/news/pressrel.
77 Id.
78 Press Release, European Patent Office, European Patent Office limits Harvard's
"oncomouse" patent (Nov. 7, 2001), available at http://www.european-patent-
office.org/news/pressrel.
79 Id.
80 See generally Hans-Rainer Jaenichen, Dr., Is It Possible to Patent Transgenic Animals
and Transgenic Plants in the European Patent Office After the Technical Board's Decision
T 356/93, "Plant Cells/PLANT GENETIC SYSTEMS"?, 14 BIOTECH. L. REP. 545 (1995) (for an
introduction to the main points ofT 356/93 before reading the original text of the decision).
81 PLANT GENETIC SYSTEMS/Glutamine synthetase inhibitors: T 356/93, 5 EUR. PAT.
OFF. REP. 357, 360 (1995).
82 Id. at 357.
83 Id.
84 Id. §40.12, at 382.
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contradicts the holding of the Examining Division on remand that a
claim to a genetically modified animal survives Article 53(b)'s limits
on patentability. The full text of disputed Claims 1, 7, 14 and 21,
along with a very simplified summary of the substance of those
claims, is necessary for understanding the contradictory holding of
T 356/93:
1. Process for controlling the action in plant cells and plants
comprising such cells of a glutamine synthetase inhibitor when the
former are contracted with the latter, which comprises causing the
stable integration in the genomic DNA of said plant cells of a
heterologous DNA including a promoter recognized by
polymerases of said plant cells and a foreign nucleotide sequence
capable of being expressed in the form of a protein in said plant
cells and plants, under the control of said promoter, and wherein
said protein has an enzymatic activity capable of causing
inactivation or neutralization of said glutamine synthetase
inhibitor.
7. Process for producing a plant or reproduction material of said
plant including a heterologous genetic material stably integrated
therein and capable of being expressed in the said plants or
reproduction material in the form of a protein capable of
inactivating or neutralizing the activity of a glutamine synthetase
inhibitor, which process comprises transforming cells or tissue of
said plants with a DNA recombinant containing a heterologous
DNA including a foreign nucleotide sequence encoding said
protein as well as the regulatory elements selected among those
which are capable of causing the stable integration of said
heterologous DNA in said plant cells or tissue and of enabling the
expression of said foreign nucleotide sequence in said plant cells
or plant tissue, regenerating plants or reproduction material of said
plants or both from the plant cells or tissue transformed with said
heterologous DNA and, optionally, biologically replicating said
last mentioned plants or reproduction material or both.
14. Plant cells, non-biologically transformed, which possess a
heterologous DNA stably integrated in their genome, said
heterologous DNA containing a foreign nucleotide sequence
encoding a protein having a non-variety specific enzymatic activity
capable of neutralizing or inactivating a glutamine synthetase
inhibitor under the control of a promoter recognized by the
polymerases of said plant cells.
21. Plant, non-biologically transformed, which possesses, stably
integrated in the genome of its cells, a foreign DNA nucleotide
2001]
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sequence encoding a protein having a non-variety-specific
enzymatic activity capable of neutralizing or inactivating a
glutamine synthetase inhibitor under the control of a promoter
recognised by the polymerases of said cells. 8
5
In brief, Claim 1, a process claim, covered a process for controlling a
GSI in plant cells and in plants containing such cells, by stably
integrating a controller enzyme encoded by foreign DNA into the
genomic DNA of the plant cells.86 Claim 7, also a process claim,
covered the method of producing a plant containing the stably
integrated foreign DNA.87 Claim 14, a product claim, covered the
plant cells containing the foreign DNA and thus expressing the
controller enzyme.8 8 Claim 21, also a product claim, covered the
plants grown from the cells of Claim 14.89
The Technical Board focused on interpreting the terms
"essentially biological process" and "microbiological process" to
determine whether the subject matter of the invention encompassed
"plant varieties." The Board first formulated an indirect definition of
an "essentially biological process" by describing which type of
process survives the exceptions to patentability under the "essentially
biological" concept, namely "a process ...comprising at least one
essential technical step, which cannot be carried out without human
intervention and which has a decisive impact on the final result." 90
Thus, plants generated following at least one essential technical step
or, better still, according to a microbiological process, do not fall
under the "essentially biological process" restriction and are
patentable.
The Board then explained "microbiological process" following
what it called an objective teleological approach-or "the principal of
equal treatment of what is of the same kind or similar" 9 1-to justify
regulating subject matter that legislators could not have anticipated.
First, the Board appreciated that modem microbiology extended
beyond such traditional processes as fermentation and
biotransformation to include also genetic engineering techniques. 92
85 Id. § I, at 360-61.
86 Dotson, supra note 1, at 935.
87 Id.
88 Id.
89 Id.
90 PLANT GENETIC SYSTEMs/Glutamine synthetase inhibitors: T 356/93, supra note 81,
§ 28, at 376.
91 Id. § 32, at 377.
92 Id. § 35, at 378.
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Second, the Board noted that the term "microorganisms" covered not
only bacterial and yeast cells, but also all cells maintained and grown
in culture in a way similar to algae, fungi, protozoa and human,
animal and plant cells.93  Third, the Board combined these
observations to conclude that "microbiological processes" comprise
"technical activities in which direct use is made of microorganisms"
94
and "'the products thereof ... encompasses products which are made
or modified by microorganisms as well as new microorganisms as
such. 95 However, the Board then restricted this definition severely
by stating that multi-step technical processes cannot be seen as
equivalents of microbiological processes simply because the former
include a microbiological step; nor can the products of such multi-
step technical processes qualify as "products thereof' within the
meaning of Article 53(b) second phrase.96
Armed with this definition, the Board held the process claims
(Claims 1 and 7) patentable because the process for introducing
recombinant DNA into the plant cells or tissue represented "an
essential technical step which has a decisive impact on the desired
final result" (i.e., not an essentially biological process, under the
Board's indirect definition of this term) despite such transformations
being dependent on chance.97 Similarly, the Board allowed product
Claim 14 because the definition of "plant varieties" does not extend to
plant cells. 98 However, the Board's rejection of Claim 21 single-
handedly overruled the Examining Division's decision on remand in
the Harvard onco-mouse case and created an extremely negative
precedent for the biotechnology industry.
The Board noted the language of Claim 21 carefully avoided
references to varieties, specific plant genes or species, 99 but the
working examples cited "genetically transformed" plant varieties as
embodiments of the invention. 100 The Board concluded Claim 21
covered modified plant varieties showing the distinctive feature and
thus was unpatentable.10° Further, the plant of Claim 21 was obtained
93 Id. § 34, at 377.
94 Id. § 35, at 378.
95 Id. § 36, at 378.
96 PLANT GENETIC SYSTEMS/Glutamine synthetase inhibitors: T 356/93, supra note 81,
§ 39, at 379.
97 Id. § 40.1, at 379-80.
98 Id. § 40.2, at 380.
99 Id. § 40.3, at 380.
100 Id. § 40.5, at 380.
101 Id. § 40.11, at 382.
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from the initial microbiological recombinant DNA transformation of
plant cells followed by the multiplication and propagation of the
transformed plant cells. 102 Hence, only the first step of the multi-step
process was microbiological, while the subsequent steps were
essentially biological. The following statement best illustrates the
repercussion of this reasoning:
No transgenic plant or animal could ever possibly be patentable
under the Board's holding because the production of a
differentiated life-form always includes essentially biological
processes. Moreover, multicelled transgenic life-forms would also
be unpatentable because patent disclosures invariably give specific
examples comprising a particular species, and production of these
inventions always requires performance on a particular species,
resulting in an unpatentable "derived variety. ' 0 3
3. Decision G 01/98
The Enlarged Board of Appeal (the highest decision-making
body of the EPO) issued Decision G 01/98 in response to a question
referred by the Technical Board of Appeal:
Does a claim which relates to plants but wherein specific plant
varieties are not individually claimed ipso facto avoid the
prohibition on patenting in Article 53(b) EPC even though it
embraces plant varieties?1°4
This question in turn arose from the Technical Board's review of an
opposition filed by Greenpeace' 0 5 to European patent No. 0436257
granted on September 14, 1994 to Novartis for an invention
controlling plant pathogens in agricultural crops. 1°6 The patent
claimed transgenic plants whose genomes were transformed with
specific foreign genes, the expression of which caused the production
of antipathogenetically active substances, and the methods of
producing such plants.'
0 7
The Enlarged Board first noted that the product claims
described the transgenic plants simply by their characteristics for
102 PLANT GENETIC SYSTEMS/Glutamine synthetase inhibitors: T 356/93, supra note 81,
§ 40.9, at 381.
103 Dotson, supra note 1, at 941.
104 NOVARTIs/Transgenic plant: G 01/98, 5 EUR. PAT. OFF. REP. 303 (2000).105 Id. § 3.9, at 318.
106 See European Patent No. 0436257 (issued Sep. 14, 1994).
107 NOVARTIS/Transgenic plant: G 01/98, supra note 104, § II, at 305.
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inhibiting the growth of plant pathogens.'0 8  The invention defined
neither a single variety nor a multiplicity of varieties, so that its
subject matter did not aim to cover a specific variety or varieties of
plants.10 9  Further, the Enlarged Board explained the patentee's
contribution as a series of steps. The first step consisted of
developing a technique for the introduction of a gene into the plant's
genome and the second step of carrying out this procedure. 110 The
patentee's choice of one suitable plant for the embodiment of his
invention did not represent a step of his contribution."' To find
otherwise would grant the inventor inappropriate protection because
the aim of genetic engineering is not the production of specific plant
varieties. 1 2  Further, the inventor disclosed a technique for
introducing the gene in all plants and not simply in a few varieties. 113
The Enlarged Board concluded the exclusion under Article 53(b)
failed to apply when the subject matter related to plants but did not
claim specific plant varieties. 1
4
III. ANALYSIS OF EP 0695351
EP 0695351 represents the most recent patent whose
interpretation by the national state courts stands to affect the
protection given to biotechnological inventions in Europe. The EPO
awarded this patent to the University of Edinburgh on December 8,
1999 for an invention relating to the method for isolation, selection,
and propagation of genetically modified animal stem cells, 115 and for
transgenic animals used in such method. 1 6 The patent includes forty-
eight claims, of which only Claims 37117 and 38118 are product claims
108 Id. § 3.1, at 313.
109 Id.
110 Id. § 3.8, at 3 18.
III Id.
112 Id.
"13 NOVARTIS/Transgenic plant: G 01/98, supra note 104, § 3.8, at 318.
"14 Id. § 3.10, at 319.
115 Stem cells are defined as such cells isolated from tissue samples which are capable of
differentiating to form certain cell types found in the adult animal. Embryonic stem cells
display the greatest ability for differentiation. EP 0695351, supra note 10.
116 Id.
117 37. An animal cell capable of being cultured to form a mixture of cells
including desired stem cells and cells other than the desired stem cells,
characterised in that all cells in the said mixture of cells contain a selectable
marker and in that in the said mixture of cells, under appropriate selective
culture conditions, differential expression of the selectable marker in (a) the
desired stem cells and (b) cells other than the desired stem cells enables
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directed to the animal cells, which pursuant to Decision T 356/93 fall
outside Article 53(b) "animal varieties" restriction to patentability. 1 9
All other claims cover methods of preparation. Unlike the Harvard
onco-mouse, the Plant Genetic Systems, and the Novartis patents, EP
0695351 includes no direct claim to a genetically modified organism;
yet its Claim 48, a process claim, ignited a flurry of controversy:
48. A method of preparing a transgenic animal, said animal
comprising a selectable marker capable of differential expression
in (a) desired stem cells and (b) cells other than desired stem cells,
the method comprising:
providing a blastocyst;
providing animal cells according to any of Claims 37 - 38;
introducing the animal cells into the blastocyst;
transferring the blastocyst to a recipient; and
allowing an embryo to develop to a chimaeric animal to
enable germline transmission of the selectable marker.
120
The interest of Claim 48 lies in the difficulty of ascertaining
whether it resulted from crafty drafting or an opportune mistake. The
patentee's representative chose not to draft Claim 48 as: 48. A
transgenic animal whose stem cells contain a selectable marker
introduced into said animal . . . or 48. A transgenic animal, which
possesses, stably integrated in the genome of its cells, a selectable
marker .... Thus, as written, Claim 48 avoids a line of prosecution
similar to that of the Harvard onco-mouse patent, where a claim to a
transgenic animal must be broad enough to encompass a taxonomic
order higher than the German term Tierarten (animal species) to
defeat the "animal varieties" bar to patentability. The patentee also
averted the EPO's objection that Article 53(b)'s second phrase
"products thereof," as an exception to the exception restoring
patentability under Article 53(a), fails to protect the products of multi-
selective survival or growth of the desired stem cells to occur, so as to
enable isolation and/or enrichment and/or propagation of desired stem cells.
Id.
118 38. An animal cell as claimed in Claim 37 wherein the selectable marker is an
antibiotic resistance gene. Id.
119 See PLANT GENETIC SYsTEMs/Glutamine synthetase inhibitors: T 356/93, supra note
81.
120 EP 0695351, supra note 10.
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step processes including microbiological and essentially biological
steps. 
121
The University of Edinburgh elected to protect its method of
preparing the transgenic animal, which seems wise in light of
T 19/90's failure to resolve whether the descendents of a patented
transgenic animal fall under the scope of protection. Indeed, an
individual would avoid the risk of infringement, brought by
replicating the method of preparing the transgenic animal, by simply
using that animal's descendents. With a protected method, the
University of Edinburgh can draft material transfer agreements and
license agreements to exercise strict control over its invention and
transgenic animal. 122 The U.S. patent granted for the same invention
offers an interesting parallel. It, too, contains no language directly
claiming the genetically modified animal; only its Claim 15 covers
"an isolated mammalian stem cell. 123
In its allowed form, Claim 48 reads as a process claim for the
method of preparing the transgenic animal. However, process claims
must satisfy the "essentially biological processes" and
"microbiological processes" limits imposed under Article 53(b).
Following the Technical Board's Decision T 356/93, the success of
such claims appeared unpredictable. When assessing the process
claim (Claim 7), the Technical Board declared:
[A]lthough the subsequent steps of regenerating and replicating the
plants or seeds make use of the "natural" machinery, the decisive
step, namely the insertion of the relevant DNA sequence into the
genome of the plant, could not occur without human
intervention .... Therefore, the process of Claim 7 as a whole is
not "essentially biological" and, thus, not excluded from
patentability under Article 53(b) EPC, first half-sentence. 24
However, further in the opinion, the Technical Board concluded that a
multi-step process could not be equated with "microbiological
processes" simply because its initial step involved a microbiological
manipulation.125 Nonetheless, the allowance of EP 0695351 Claim 48
seems justified under the Enlarged Board's statement in Decision
G 01/98: "To escape the prohibition of Article 53(b) EPC, the
121 See holding ofT 356/93 analyzed under Part II.B.2.
122 Telephone Interview with Dr. Carol A. Stratford, Ph.D., J.D., Vice President,
Intellectual Property, Galileo Laboratories, Inc. (Jan. 7, 2001).
123 U.S. Patent No. 6,146,888 (issued Nov. 14, 2000).
124 PLANT GENETIC SYSTEMS/Glutamine synthetase inhibitors: T 356/93, supra note 81,
§ 40.1, at 379-80.
125 Id. § 40.9, at 381-82.
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approach adopted in Article 2 no. 2 of the draft E.C. Biotechnology
Directive would require at least one clearly identified non-biological
process step but would allow any number of additional essentially
biological steps."'' 26  It is interesting to note that the patentee
described every step of the method, thus suggesting at least four
manipulations requiring "human intervention," when more simply,
the invention consists of transfecting embryonic animal cells with the
selectable marker and using the animal's biological reproductive
system to develop a chimeric animal showing that characteristic.
An analysis of EPC Article 64(2) outlines the deftness of the
patentee's representative for claim drafting. As explained above,
Claim 48 relates to the method of preparation and not to the
transgenic animal itself. However, Article 64(2) reads: "If the
subject-matter of the European patent is a process, the protection
conferred by the patent shall extend to the products directly obtained
by such process."'127  Thus, the patentee circumvents the EPO's
possible objection that the genetically modified animal does not
qualify as the product of a "microbiological process," and indirectly
protects the transgenic animal. However, the Technical Board in
Decision T 356/93 declared: "A claim is not allowable if the grant of
a patent in respect of the invention defined in said claim is conducive
to an evasion of a provision of the EPC establishing an exception to
patentability., 128 This statement resonates as an empty warning in
view of the Enlarged Board's structural argument, in Decision
G 01/98, that under the EPC, the national patent courts, which are
already responsible for examining interpretation and infringement
issues, shall apply the provisions of Article 64(2):
The requirements on patentability to be examined by the EPO are
contained in Part II, Chapter I EPC (Arts 52-57); Article 64 (2)
EPC belongs to Part II, Chapter III, containing provisions
concerning the effects of patents and patent applications and is to
be applied by the courts responsible for deciding on infringement
cases. 129
Therefore, Article 64(2) also fails to raise a consequential obstacle to
the allowance of Claim 48.
126 NOVARTIs/Transgenic plant: G 01/98, supra note 104, § III (c), at 307.
127 EPC, supra note 12, art. 64(2).
128 PLANT GENETIC SYSTEMs/Glutarnine synthetase inhibitors: T 356/93, supra note 81,
§ 40.7, at 381.
129 NOVARTts/Transgenic plant: G 01/98, supra note 104, § XI 4., at 320.
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EPC Article 64 may not bar the allowance of Claim 48, but this
article delineates the greatest controversy surrounding this claim.
Indeed, if the national patent courts rule on matters of interpretation
and infringement, then their decisions as to EP 0695351 Claim 48
may vary along with which of the three equally binding languages of
the EPC they review. More specifically, the three versions of Claim
48 read: "A method of preparing a transgenic animal, ' 1 30 "Proc&d6 de
pr4paration d'un animal transg~nique,"'131 and "Verfahren zur
Herstellung eines transgenetischen Tieres,"' 32 in English, French and
German respectively. The definition of the French term animal
translates as "(general concept, including man) a living being gifted
with sensibility and mobility, ,133 and the German term Tier as "living
organism which nourishes itself from organic matter, and which is
capable of moving and reacting to stimuli.' 34 One of the definitions
for the English term "animal" reads: "a multicellular organism of the
kingdom Animalia, characterized by a capacity for locomotion,
nonphotosynthetic metabolism, pronounced response to stimuli,
restricted growth, and fixed bodily structure.' 35 A second definition
states: "an animal organism other than a human being."'136 Thus,
absent the qualifier "non-human" in all three versions of Claim 48,
there exists no single and definite interpretation, and Claim 48 may be
read as: "A method of preparing a transgenic human animal" (i.e., a
human clone) in all three texts 137 (contrary to the EPO's released
statement which reported the possibility of such a reading for the
English text only).138
The University of Edinburgh obtained EP 0695351 on December
8, 1999 and the EPO issued the following press release in January
2000:
130 EP 0695351, supra note 10.
131 Id.
132 Id.
133 (Concept gdngral, incluant l'homme) Etre vivant organise, doug de sensibilitM et de
motilitd. LE NOUVEAU PETIT ROBERT 84 (3rd ed. 1996).
134 Lebewesen, das sich von organischen Stoffen nahrt u. sich bewegen u. auf Reize
reagieren kann. DEUTSCHES WORTERBUCH col. 3566 (2nd ed. 1971).
135 THE AMERICAN HERITAGE DICTIONARY 53 (3rd ed. 1993).
136 Id.
137 Note that the claims of the U.S. patent granted for the Harvard onco-mouse include
the qualifier "non-human." U.S. Patent No. 4,736,866 (issued Apr. 12, 1988).
138 Press Release, European Patent Office, Declaration of the European Patent Office
with regard to Patent No. EP 0695351 granted on 8 December 1999 (Feb. 22, 2000), available
at http://www.european-patent-office.org/news/pressrel.
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The European Patent Office has already admitted this error and
regrets that it has occurred. The Office will take every care to
prevent such errors recurring in the future. Contrary to many
accounts, and despite the omission of the qualifier "(non-human),"
the scope of protection of Patent No. EP 0695351 does not extend
to human cloning. That is because under Articles 69139 and 84140
of the European Patent Convention the patent claims must be
supported by the patent description. This is not the case here. 141
Nonetheless, the description for EP 0695351 seems to support this
reading of Claim 48 in light of its sentence: "In the context of this
invention, the term 'animal cell' is intended to embrace all animal
cells, especially of mammalian species, including human cells."
142
Thus, if the term "animal cells" covers "human cells," then the words
"animal" and "human" are to be equated throughout the description
and claims. Further, the Enlarged Board in Decision G 01/98
declared that: "On the contrary, the Directive of the European
Parliament and of the Council on the legal protection of
biotechnological inventions . . . establishes that promotion of
innovation in this field is considered necessary in Europe.,
143
In conclusion of the analysis, EP 0695351 Claim 48 seems more
the result of a calculated procedure by both sides (patentee and EPO)
than the product of inadvertence. However, if the reader still believes
Claim 48 was issued from an oversight of the EPO Examining
Division, this Comment's conclusion evaluates whether the EPC
provisions could rectify the dangerous precedent EP 0695351 will set
if left in its presently granted form.
IV. CONCLUSION
Since the grant of EP 0695351 on December 8, 1999, the EPO
has received fourteen notices of opposition to this patent (in brief,
139 Article 69- Extent of protection
The extent of the protection conferred by a European patent or a European
patent application shall be determined by the terms of the claims.
Nevertheless, the description and drawings shall be used to interpret the
claims.
EPC, supra note 12, art. 69.
140 Article 84- The claims
The claims shall define the matter for which protection is sought. They shall
be clear and concise and be supported by the description.
Id. art. 84.
141 EPO press release dated Feb. 22, 2000, supra note 138.
142 EP 0695351, supra note 10.
143 NOVARTIS/Transgenic plant: G 01/98, supra note 104, § 3.9, at 318-19.
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from environmental agencies, religious groups, political parties,
Germany's Ministry of Justice, Pro-Life groups, and the Government
of the Republic of Italy). 144 The EPO informed the University of
Edinburgh of the oppositions on December 27, 2000 and granted an
eight-month reply period. 145 As of December 12, 2001, the EPO had
ruled favorably on the admissibility of four such notices of opposition
and scheduled oral proceedings for April 22, 2002.146
One or more of these opposition procedures may finally prove
fatal to EP 0695351 Claim 48. Indeed, an attack on Claim 48 can rest
on at least two grounds for opposition listed under Article 100: "the
European patent does not disclose the invention in a manner
sufficiently clear and complete for it to be carried out by a person
skilled in the art," or "the subject-matter of the European patent is not
patentable within the terms of Articles 52 to 57 .'' 47
Under the first ground, an opponent would argue the broadest
reading of Claim 48 covers a method of preparing all transgenic
animals, which in the absence of the qualifier "non-human" includes
transgenic human animals (or human cloning). However, the patent
description focuses solely on mice as a preferred embodiment of the
invention. Thus, the Opposition Division may decide that a person of
ordinary skill in the art could not successfully extrapolate the method
from production of transgenic mice to human cloning, and thus order
the patentee to amend Claim 48 (revocation seems too strong of a
remedy). However, the claimed invention relates to the isolation,
selection and propagation of animal transgenic stem cells and not to
the transgenic animal as such, so that the working examples using
mice could suffice to enable the method of Claim 48.
Under the second ground of opposition, an opponent would
argue most likely that Claim 48 violates EPC Article 53(a)'s "ordre
144 List of entities that filed notices of opposition: Greenpeace Deutschland e.V., PDS-
Bundestagsfraktion, Okumenischer Rat der Kirchen in Osterreich, Bundesrepublik Deutschland
Bundesministerium der Justiz z.H. Dr. E. Hucko, Alliance Pour les Droits de la Vie, Aktion
Leben Osterreich, Greenpeace e.V. Sammeleinspruch, Biindnis 90 Die Gruinen-
Bundestagsfraktion Dr. B. Laubach, Dr. Ruth Tippe "Kein Patente auf Leben," Het Koninkrijk
der Nederlanden, Deutsche Forschungsgemeinschafl, Regierung der Republik Italien
Unterstaatssekretgqr Dr. Enrico Micheli, Dr. Jirgen Kaiser, Bfindnis 90/Die Grilnen Ortsverband
Vaihingen Kreisverband. European Patent Register, at http://www.epoline.org/register.html
(last updated Dec. 12, 2001) (search for publication number EP069535 1).
145 Id
146 List of entities that filed admissible notices of opposition according to the EPO:
Greenpeace Deutschland e.V., Okumenischer Rat der Kirchen in Osterreich, Bundesrepublik
Deutschland Bundesministerium der Justiz z.H. Dr. E. Hucko, Regierung der Republik Italien
Unterstaatssekretar Dr. Enrico Micheli. Id.
147 EPC, supra note 12, art. 100.
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public" or morality exception to patentability. 41 In its initial opinion
rejecting the Harvard onco-mouse patent application, the Examining
Division defined the purpose of the "ordre public" or morality
limitation as serving "to exclude from protection inventions likely to
induce riot or public disorder, or to lead to criminal or other generally
offensive behaviour."'149 Certainly, an interpretation of Claim 48 as
covering human cloning will satisfy this definition. However, the
Technical Board in Decision T 19/90.offered the following balancing
test to guide the Examining Division in assessing Article 53(a)
violations: "The decision as to whether or not Article 53(a) EPC is a
bar to patenting the present invention would seem to depend mainly
on a careful weighing up of the suffering of animals and possible
risks to the environment on the one hand, and the invention's
usefulness to mankind on the other.' 50  The description of EP
0695351 states the invention proposes a method for isolating stem
cells from tissue samples using a selectable marker (e.g., an
oncogene), which stem cells are then used for research or medical
procedures. 5 ' Thus, the patentee may argue that the stem cells can be
used to test suspected carcinogens and the protecting effect of
antioxidants, so that like the Harvard onco-mouse, the invention
contributes to the treatment of cancer.
The outcome of the opposition procedures is difficult to predict.
Interestingly, the EPO revoked the Novartis patent (EP 0436257) on
May 10, 2000, following oral proceedings. The Opposition Division
justified its decision by stating the claims failed the novelty
requirement under the EPC provisions because of public prior use in
India. 52 Novartis had received its European patent shortly before the
grant of EP 0695351, and together these patents rekindled the
controversy over life-patents in Europe. Perhaps the only certainty
related to Claim 48 rests in its possible invalidation through the
national patent courts. For those nations outwardly banning human
cloning, the hypothesized reading of Claim 48 as "A method for
preparing a transgenic human animal" will bring its definite end.
The following oral statement by the President of the EPO, Mr.
Ingo Kober, on June 27, 2000, like the above mentioned EPO press
148 Id. art. 53(a).
149 HARVARD/Onco-mouse: Application 85 304 490.7, supra note 47, § 10.2, at 11.
150 HARVARD/Onco-mouse: T 19/90, supra note 49, § 5, at 513.
151 EP 0695351, supra note 10.
152 Press Release, European Patent Office, "Neem tree oil" case: European patent No.
0436257 revoked (May 10, 2000), available at http://www.european-patent-
office.org/news/pressrel.
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release acknowledging the EPO's mistake while prosecuting EP
0695351, illustrates that the controversy surrounding patent
protection for genetically modified organisms in Europe may be more
serious than the EPO initially envisaged:
The patent system cannot decide whether a technology is
permissible; the responsibility for considering and resolving such
questions lies with quite different branches of the law. Nor do
patent offices issue safety certificates. Dangerous or ethically
questionable technology cannot be held in check with the help of
patent law.
The idea that the EPO has been deliberately breaking the law is
also contradicted by the extensive system of checks via opposition
and appeal proceedings after grant and revocation proceedings
before national courts: in Germany, for example, before the
Federal Patents Court at first instance, with the possibility of
appeal to the Federal Court of Justice. Despite all claims to the
contrary, European patents - and the activities of the European
Patent Office - are subject to numerous independent controls and
checks at both national and international level. 53
Mr. Kober also invites critics to observe the recent changes in
European patent law. He cites the E.C. Biotechnology Directive,
154
approved in its final form in 1998, which offers guidelines for the
protection of biotechnological inventions and recognizes the
fundamental importance of such inventions for the industrial
development of Europe.155 Furthermore, a Diplomatic Conference
was held in late November 2000 to revise the EPC provisions.
156
Notably as a result of this Conference, the EPO will offer a patentee
the option of electing a central procedure for limiting the protection
afforded by the patent, should such a patent be found invalid, thus
153 Press Release, European Patent Office, Comments on genetic engineering (Excerpt
from the address of the President of the EPO, Mr. Ingo Kober, on 27 June at the annual press
conference of the Office in Munich) (June 27, 2000), available at http://www.european-patent-
office.org/news/pressrel.
154 Id.
155 Council Directive 98/44 of 6 July 1998 on the legal protection of biotechnological
inventions, 1998 O.J. (L 213) 1, available at http://europa.eu.int/eur-
lex/en/lif/dat/1998/en_398L0044.html (July 30, 1998).
156 Press Release, European Patent Office, Opening of the Diplomatic Conference to
revise the EPC (Nov. 20, 2000), available at http://www.european-patent-
office.org/news/pressrel.
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avoiding national patent offices and courts altogether. 57  The
Chairman of the Administrative Council of the EPO explained: "This
limitation option not only answers long-standing calls for such a
procedure from experts in the field, but is also in the public interest,
as evidenced by the controversy surrounding certain biotechnology
patents. It will act as an incentive to amend incorrectly granted
patents quickly and at low cost. 1 58  Nonetheless, the E.C.
Biotechnology Directive demands that European countries comply
with its text and the EPC contracting states have yet to ratify the
Conference's new provisions.159  Thus, until Europe can claim a
complete harmonization of its patent laws, Europe seems destined to
remain a second player to the United States in the biotechnology
industry.
157 Press Release, European Patent Office, Statement by Dr Roland Grossenbacher,
Chairman of the Administrative Council of the European Patent Organisation (Nov. 29, 2000),
available at http://www.european-patent-office.org/news/pressrel.
158 Id.
159 Id.
